For Form 2: Antimicrobial Susceptibility Testing, the annual frequency of responses per respondent is 1,452 (121 isolates \times 12\) months). Based on previous laboratory experience, the estimated burden of completing Form 2 for each participating laboratory is 1 hour per response, which includes the time required for laboratory processing of the patient’s isolate, gathering and maintaining the data needed, and completing and reviewing the collection of information. For Form 3: Control Strain Susceptibility Testing, a “response” is defined as the processing and recording of Regional laboratory data for a set of seven control strains. It takes approximately 12 minutes to process and record the Regional laboratory data on Form 3 for one set of seven control strains, of which there are 4 sets. The number of responses per respondent is 48 (4 sets \times 12\) months). There are no additional costs to respondents.

### ESTIMATE OF ANNUALIZED BURDEN HOURS

<table>
<thead>
<tr>
<th>Type of respondent</th>
<th>Form name</th>
<th>Number of responses per respondent</th>
<th>Avg. burden per response (in hours)</th>
<th>Total annual burden (in hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinic ...............</td>
<td>Demographic Clinical Data Form 1 ..............</td>
<td>30</td>
<td>11/60</td>
<td>1,320</td>
</tr>
<tr>
<td>Laboratory ..........</td>
<td>Antimicrobial Susceptibility Testing Form 2 ......</td>
<td>5</td>
<td>1</td>
<td>7,260</td>
</tr>
<tr>
<td></td>
<td>Control Strain Susceptibility Testing Form 3 ......</td>
<td>5</td>
<td>12/60</td>
<td>48</td>
</tr>
<tr>
<td>Total ...............</td>
<td>.....................................................</td>
<td>40</td>
<td>.............................................</td>
<td>8,628</td>
</tr>
</tbody>
</table>

Dated: March 21, 2013.

Ron A. Otten,
Director, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.

[FR Doc. 2013–07059 Filed 3–26–13; 8:45 am]

BILLING CODE 4163–18–P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee on Breast Cancer in Young Women (ACBCYW)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

**Time and Date:** 9:00 a.m.–11:00 a.m. EDT, April 16, 2013.

**Place:** The meeting will be held via teleconference.

Teleconference login information is as follows: For Public: TOLL–FREE PHONE #: 800–857–4875 Participant passcode: 9377 Net Conference URL: https://www.mymeetings.com/ac/join/ Conference number: PW8921926 Audience passcode: 9377 or Public can join the event directly: https://www.mymeetings.com/ac/join.php?e=PW8921926&p=9377&l=c

There is also a toll for anyone outside of the USA: TOLL #: 1–212–287–1661 Participant passcode: 9377

Please go to the ACBCYW meeting Web page to register for this meeting: http://www.cdc.gov/cancer/breast/what_cdc_is_doing/conference.htm.

**Status:** Open to the public, limited only by the number of phone lines available.

**Purpose:** The committee provides advice and guidance to the Secretary, HHS; the Assistant Secretary for Health; and the Director, CDC, regarding the formative research, development, implementation and evaluation of evidence-based activities designed to prevent breast cancer (particularly among those at heightened risk) and promote the early detection and support of young women who develop the disease. The advice provided by the Committee will assist in ensuring scientific quality, timeliness, utility, and dissemination of credible appropriate messages and resource materials.

**Matters To Be Discussed:** The agenda will include discussions on approaches to increase awareness of clinicians/practitioners regarding topics such as breast health, symptoms, diagnosis, and treatment of breast cancer in young women; and information needs and delivery mechanisms for women at higher risks for developing breast cancer. These discussions will be directed toward the final review and approval of formal recommendations on these topics.

Agenda items are subject to change as priorities dictate.

**Contact Person for More Information:** Temeseik L. Fairley, Ph.D., Designated Federal Officer, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway NE., Mailstop K52, Atlanta, Georgia, 30341, Telephone (770) 488–4518, Fax (770) 488–4760, Email: acbcyw@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention, and Agency for Toxic Substances and Disease Registry.

Dana Redford,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2013–06946 Filed 3–26–13; 8:45 am]

BILLING CODE 4163–18–P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Respirator Certification Fees; Public Meeting

**AGENCY:** The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of public meeting.

**SUMMARY:** The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces a public meeting. The purpose of this meeting is to allow stakeholders to present information the impact of an increase on respirator fees on individual respirator manufacturers, the respirator market, or on those industries that rely on NIOSH approved respiratory equipment.

**DATES:** April 30, 2013, 10 a.m. to 4 p.m. EDT, or after the last public commenter has spoken, whichever occurs first.

**ADDRESSES:** U.S. Office of Surface Mining, Three Parkway Center